Lumida
/TWST
⌘K
Twist Bioscience Corp

Twist Bioscience Corp

TWST
$93.85USD↑+2.87%+2.62 today

MARKET CAP

5.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$85 – $94

52W RANGE

$23
$105

AI Summary

Stalk
StalkMedium

TWST remains in a Stage 2 advancing uptrend anchored by higher highs/lows and rising EMAs, but a Blow-Off Top exhaustion at fresh highs amid extreme overbought readings has produced a near-term rejection candle. Short-term timing is unfavorable for new long entries, so execution is deferred. We will stalk for a corrective pullback into the rising 9/20 EMA support zone and look for clear acceptance before participating.

  • ↑Q2 2026 revenue +19.3% YoY to $110.7 M, DNA solutions +28%.
  • ↑Gross margin expanded to 51.6% with adjusted EBITDA breakeven expected in Q4.
  • ↓Negative earnings yield and weak profitability metrics question ROI sustainability.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Twist Bioscience Corporation (NASDAQ: TWST) is a leading biotechnology company specializing in synthetic DNA production and next-generation sequencing (NGS) applications. By leveraging its proprietary silicon-based DNA synthesis technology, Twist provides innovative solutions across various sectors, including drug discovery, diagnostics, and synthetic biology. Positioned at the forefront of the rapidly advancing AI-enhanced drug discovery market, Twist’s expansive capabilities attract a diverse clientele ranging from major pharmaceutical firms to academic research institutions.

Bull says

  • ↑Q2 2026 revenue +19.3% YoY to $110.7 M, DNA solutions +28%.
  • ↑Gross margin expanded to 51.6% with adjusted EBITDA breakeven expected in Q4.
  • ↑AI-driven drug discovery orders grew >$25 M vs. FY 2024, boosting customer demand.
  • ↑Ended Q2 with $171.7 M cash and short-term investments for runway.
  • ↑Analyst price targets raised from $38 to $82.50, signaling bullish revisions.
  • ↑Proprietary silicon-based DNA tech underpins strong growth and high liquidity.

Bear says

  • ↓Negative earnings yield and weak profitability metrics question ROI sustainability.
  • ↓Operating expenses rose to $95.8 M, risking margin compression if growth stalls.
  • ↓Top 10 customers account for ~36% of NGS revenue, concentration risk.
  • ↓Short interest at 0.38 and high volatility suggest investor skepticism.
  • ↓Academic funding pressures may create Q4 $5 M revenue air pocket.
  • ↓Low institutional ownership and sensitivity to rising rates amplify downside risk.

Investment themes with TWST

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 06-15-2026neutral

Transcript signals

Bull points

  • We know there's about a $1.4 billion opportunity to convert the makers into buyers, which is underpinned by economics and speed, making the value proposition start to resonate strongly.
  • So we continue to be very, very optimistic and bullish looking forward.
  • So we did announce that we expect to be adjusted EBITDA positive by the end of fiscal 2026, with a clear path to that following the Atlas announcement.

Bear points

  • be understanding and respectful of the fact that there is uncertainty and we have baked in what we know today around the tariffs.
  • However, since May of 2023, we have intentionally constrained our spending in DNA data storage to keep twist over our investment in this business to less than $25 million annually.
  • Operating expenses excluding cost of revenues for the second quarter were approximately $87.6 million compared to approximately $79.8 million in the same period of 2024, driven by a $5.5 million increase in non-cash stock-based compensation.
Read full transcript analysis ›